TY - JOUR
T1 - The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection
T2 - Baseline Imaging Findings in High-Risk Individuals
AU - behalf of the PRECEDE Consortium
AU - Zogopoulos, George
AU - Haimi, Ido
AU - Sanoba, Shenin A.
AU - Everett, Jessica N.
AU - Wang, Yifan
AU - Katona, Bryson W.
AU - Farrell, James J.
AU - Grossberg, Aaron J.
AU - Paiella, Salvatore
AU - Klute, Kelsey A.
AU - Bi, Yan
AU - Wallace, Michael B.
AU - Kwon, Richard S.
AU - Stoffel, Elena M.
AU - Wadlow, Raymond C.
AU - Sussman, Daniel A.
AU - Merchant, Nipun B.
AU - Permuth, Jennifer B.
AU - Golan, Talia
AU - Raitses-Gurevich, Maria
AU - Lowy, Andrew M.
AU - Liau, Joy
AU - Jeter, Joanne M.
AU - Lindberg, James M.
AU - Chung, Daniel C.
AU - Earl, Julie
AU - Brentnall, Teresa A.
AU - Schrader, Kasmintan A.
AU - Kaul, Vivek
AU - Huang, Chenchan
AU - Chandarana, Hersh
AU - Smerdon, Caroline
AU - Graff, John J.
AU - Kastrinos, Fay
AU - Kupfer, Sonia S.
AU - Lucas, Aimee L.
AU - Sears, Rosalie C.
AU - Brand, Randall E.
AU - Parmigiani, Giovanni
AU - Simeone, Diane M.
N1 - Publisher Copyright:
© 2024 Harborside Press. All rights reserved.
PY - 2024/4
Y1 - 2024/4
N2 - Background: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To address this unmet clinical need and drive early diagnosis research, we established the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Methods: PRECEDE is a multi-institutional international collaboration that has undertaken an observational prospective cohort study. Individuals (aged 18–90 years) are enrolled into 1 of 7 cohorts based on family history and pathogenic germline variant (PGV) status. From April 1, 2020, to November 21, 2022, a total of 3,402 participants were enrolled in 1 of 7 study cohorts, with 1,759 (51.7%) meeting criteria for the highest-risk cohort (Cohort 1). Cohort 1 HRIs underwent germline testing and pancreas imaging by MRI/MR-cholangiopancreatography or endoscopic ultrasound. Results: A total of 1,400 participants in Cohort 1 (79.6%) had completed baseline imaging and were sub-classified into 3 groups based on familial PC (FPC; n5670), a PGV and FPC (PGV1/FPC1; n5115), and a PGV with a pedigree that does not meet FPC criteria (PGV1/FPC–; n5615). One HRI was diagnosed with stage IIB PC on study entry, and 35.1% of HRIs harbored pancreatic cysts. Increasing age (odds ratio, 1.05; P,.001) and FPC group assignment (odds ratio, 1.57; P,.001; relative to PGV1/FPC–) were independent predictors of harboring a pancreatic cyst. Conclusions: PRECEDE provides infrastructure support to increase access to clinical surveillance for HRIs worldwide, while aiming to drive early PC detection advancements through longitudinal standardized clinical data, imaging, and biospecimen captures. Increased cyst prevalence in HRIs with FPC suggests that FPC may infer distinct biological processes. To enable the development of PC surveillance approaches better tailored to risk category, we recommend adoption of subclassification of HRIs into FPC, PGV1/FPC1, and PGV1/FPC– risk groups by surveillance protocols.
AB - Background: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To address this unmet clinical need and drive early diagnosis research, we established the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Methods: PRECEDE is a multi-institutional international collaboration that has undertaken an observational prospective cohort study. Individuals (aged 18–90 years) are enrolled into 1 of 7 cohorts based on family history and pathogenic germline variant (PGV) status. From April 1, 2020, to November 21, 2022, a total of 3,402 participants were enrolled in 1 of 7 study cohorts, with 1,759 (51.7%) meeting criteria for the highest-risk cohort (Cohort 1). Cohort 1 HRIs underwent germline testing and pancreas imaging by MRI/MR-cholangiopancreatography or endoscopic ultrasound. Results: A total of 1,400 participants in Cohort 1 (79.6%) had completed baseline imaging and were sub-classified into 3 groups based on familial PC (FPC; n5670), a PGV and FPC (PGV1/FPC1; n5115), and a PGV with a pedigree that does not meet FPC criteria (PGV1/FPC–; n5615). One HRI was diagnosed with stage IIB PC on study entry, and 35.1% of HRIs harbored pancreatic cysts. Increasing age (odds ratio, 1.05; P,.001) and FPC group assignment (odds ratio, 1.57; P,.001; relative to PGV1/FPC–) were independent predictors of harboring a pancreatic cyst. Conclusions: PRECEDE provides infrastructure support to increase access to clinical surveillance for HRIs worldwide, while aiming to drive early PC detection advancements through longitudinal standardized clinical data, imaging, and biospecimen captures. Increased cyst prevalence in HRIs with FPC suggests that FPC may infer distinct biological processes. To enable the development of PC surveillance approaches better tailored to risk category, we recommend adoption of subclassification of HRIs into FPC, PGV1/FPC1, and PGV1/FPC– risk groups by surveillance protocols.
UR - https://www.scopus.com/pages/publications/85190903756
U2 - 10.6004/jnccn.2023.7097
DO - 10.6004/jnccn.2023.7097
M3 - Article
C2 - 38626807
AN - SCOPUS:85190903756
SN - 1540-1405
VL - 22
SP - 158
EP - 166
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 3
ER -